Amplia Therapeutics Past Earnings Performance
Past criteria checks 0/6
Amplia Therapeutics's earnings have been declining at an average annual rate of -24.7%, while the Biotechs industry saw earnings growing at 12.8% annually. Revenues have been growing at an average rate of 47.1% per year.
Key information
-24.7%
Earnings growth rate
20.9%
EPS growth rate
| Biotechs Industry Growth | 9.6% |
| Revenue growth rate | 47.1% |
| Return on equity | -30.2% |
| Net Margin | -238.7% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully
Jan 13
Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Apr 28Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings
Feb 28Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Jan 06
Revenue & Expenses BreakdownBeta
How Amplia Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 2 | -4 | 3 | 3 |
| 30 Jun 23 | 2 | -5 | 3 | 4 |
| 31 Mar 23 | 1 | -6 | 2 | 5 |
| 31 Dec 22 | 2 | -6 | 2 | 5 |
| 30 Sep 22 | 3 | -5 | 2 | 6 |
| 30 Jun 22 | 2 | -4 | 2 | 5 |
| 31 Mar 22 | 2 | -4 | 2 | 4 |
| 31 Dec 21 | 2 | -3 | 2 | 3 |
| 30 Sep 21 | 1 | -3 | 1 | 3 |
| 30 Jun 21 | 1 | -3 | 1 | 2 |
| 31 Mar 21 | 2 | -2 | 1 | 2 |
| 31 Dec 20 | 1 | -2 | 1 | 2 |
| 30 Sep 20 | 1 | -2 | 1 | 2 |
| 30 Jun 20 | 0 | -2 | 1 | 1 |
| 31 Mar 20 | 0 | -2 | 1 | 1 |
| 31 Dec 19 | 0 | -2 | 1 | 1 |
| 30 Sep 19 | 0 | -2 | 1 | 1 |
| 30 Jun 19 | 0 | -2 | 1 | 1 |
| 31 Mar 19 | 0 | -2 | 1 | 1 |
| 31 Dec 18 | 0 | -2 | 1 | 1 |
| 30 Sep 18 | 0 | -3 | 1 | 1 |
| 30 Jun 18 | 0 | -3 | 1 | 2 |
| 31 Mar 18 | 1 | -4 | 2 | 3 |
| 31 Dec 17 | 1 | -5 | 2 | 4 |
| 30 Sep 17 | 1 | -6 | 2 | 5 |
| 30 Jun 17 | 2 | -7 | 2 | 6 |
| 31 Mar 17 | 2 | -7 | 3 | 6 |
| 31 Dec 16 | 2 | -7 | 3 | 6 |
| 30 Sep 16 | 3 | -6 | 2 | 6 |
| 30 Jun 16 | 2 | -6 | 2 | 5 |
| 31 Mar 16 | 2 | -5 | 2 | 5 |
| 31 Dec 15 | 2 | -5 | 2 | 4 |
| 30 Sep 15 | 1 | -5 | 2 | 3 |
| 30 Jun 15 | 0 | -5 | 2 | 2 |
| 31 Mar 15 | 0 | -5 | 2 | 2 |
| 30 Jun 14 | 0 | -5 | 1 | 1 |
Quality Earnings: ATX is currently unprofitable.
Growing Profit Margin: ATX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ATX is unprofitable, and losses have increased over the past 5 years at a rate of 24.7% per year.
Accelerating Growth: Unable to compare ATX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.6%).
Return on Equity
High ROE: ATX has a negative Return on Equity (-30.23%), as it is currently unprofitable.